Future Perspectives in Detecting EGFR and ALK Gene Alterations in Liquid Biopsies of Patients with NSCLC

International Journal of Molecular Sciences

Raquel Chaves¹  Filomena Adega¹  Juliana Miranda¹  Daniela Ferreira¹  Paula Martins-Lopes¹ 

[1] Biosystems and Integrative Sciences Institute (BioISI), Faculty of Sciences,University of Lisboa, 1749-016 Lisbon, Portugal;

关键词: non-small-cell lung cancer;    EGFR;    ALK;    predictive biomarkers;    liquid biopsies;    next-generation sequencing;   

DOI  :  10.3390/ijms22083815

来源: DOAJ

【 摘 要 】

Non-small-cell lung cancer (NSCLC) is a major cause of death worldwide. Alterations in such genes as EGFR and ALK are considered important biomarkers in NSCLC due to the existence of targeted therapies with specific tyrosine kinase inhibitors (TKIs). However, specific resistance-related mutations can occur during TKI treatment, which often result in therapy inefficacy. Liquid biopsies arise as a reliable tool for the early detection of these types of alterations, allowing a non-invasive follow-up of the patients. Furthermore, they can be essential for cancer screening, initial diagnosis and to check surgery success. Despite the great advantages of liquid biopsies in NSCLC and the high input that next-generation sequencing (NGS) approaches can provide in this field, its use in oncology is still limited. With improvement of assay sensitivity and the establishment of clinical guidelines for liquid biopsy analysis, it is expected that they will be used in routine procedures. This review focuses on the usefulness of liquid biopsies of NSCLC patients as a means to detect alterations in EGFR and ALK genes and in disease management, highlighting the impact of NGS methods.

【 授权许可】

Unknown